Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | PPARD | Q03181 | 8/20 | 0.35 |
| ▸ | PPARA | Q07869 | 8/20 | 0.35 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6034670 | 0.90 | KDM4E (0.42) | SMN1; SMN2KDM4EHPGDLMNANPC1 | |
| SCHEMBL6036232 | 0.90 | SMN1; SMN2 (0.40) | SMN1; SMN2KDM4EHPGDLMNANPC1 | |
| SCHEMBL6035764 | 0.90 | HCRTR1 (0.36) | SMN1; SMN2KDM4EHPGDLMNANPC1 | |
| SCHEMBL6036155 | 0.89 | HCRTR1 (0.36) | SMN1; SMN2KDM4EHPGDLMNANPC1 | |
| SCHEMBL6035813 | 0.89 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EHPGDLMNANPC1 | |
| SCHEMBL1632906 | 0.88 | GCGR (0.34) | SMN1; SMN2KDM4EHPGDLMNANPC1 | |
| SCHEMBL6035046 | 0.87 | HCRTR1 (0.36) | SMN1; SMN2KDM4EHPGDLMNANPC1 | |
| SCHEMBL6035760 | 0.87 | SMN1; SMN2 (0.43) | SMN1; SMN2KDM4EHPGDLMNAPPARD | |
| SCHEMBL6035895 | 0.86 | KDM4E (0.43) | SMN1; SMN2KDM4EHPGDLMNANPC1 | |
| SCHEMBL6035616 | 0.86 | PPARD (0.41) | SMN1; SMN2KDM4EPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | SMN1; SMN2 4408/4885KDM4E 509/4885HPGD 3297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.